Clovis and BMS research small molecule and antibody combination.
Speculation mounting that Pfizer and others could try for $90 bn plus merger
French biotech developing cancer immunotherapy with BMS.
No fast approval for immunotherapy combo in first line use.
Companies announce eye-catching R&D plans ahead of conference.